Navigation Links
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting

nificant and clinically meaningful efficacy in the treatment of LUTS secondary to BPH; - No statistically significant impact on quality of life or erectile function; and - Intramuscular 15 mg + 15 mg was the most effective regimen in this study. About Ozarelix and Partnerships

Ozarelix is a fourth generation luteinizing hormone-releasing hormone (LHRH) antagonist administered as a depot formulation for the treatment of benign and malign hormone-dependent diseases. It is currently in Phase 2b clinical trials for both BPH and prostate cancer.

In August 2004, AEterna Zentaris granted Spectrum Pharmaceuticals an exclusive license to develop and market ozarelix for all potential indications in North America and India, while AEterna Zentaris retains exclusive rights to the rest of the world. Spectrum will also receive 50% of any upfront and milestone payments, royalties and/or profits from sales of the product in Japan.

Furthermore, AEterna Zentaris recently granted Japanese rights for all potential oncology indications to Nippon Kayaku, a key player in the Japanese oncology market.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate frequently occurring in men over the age of 50. The enlargement can result in the gradual squeezing of the urethra, resulting in increased frequency or difficulty in urinating. Enlargement of the prostate is controlled by testosterone. According to the National Institutes of Health, BPH affects more than 50% of men over the age of 60 and as many as 90% of men over the age of 70. Treatment options for BPH include surgery and medications to reduce the amount of tissue and increase the flow of urine. Current treatment options are inconvenient, leading to ineffective compliance and are only effective in roughly half of the patients treated. According to Decision Resource, in 2004, the total prevalence cases
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... SANTA CLARA, Calif., Aug. 15, 2011 NewCardio, Inc., (OTC ... results for the second quarter ended June 30, 2011. More ... Quarterly Report on Form 10-Q, filed today with the Securities ... QTinno® was selected by a top 5 global pharmaceutical company ...
... Aug. 15, 2011 Millennium HealthCare ... KBL, LLP, a Public Company Accounting Oversight Board (PCAOB) ... KBL, LLP provides a combination of ... emerging businesses. Their professionals maintain an entrepreneurial spirit and ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8Millennium HealthCare Inc. Engages KBL, LLP 2
(Date:12/24/2014)... 2014 For chic ladies, new fashionable outfits ... part of their Holiday Wish List, Angeldress.co.uk has ... ways to accent ladies’ holiday wardrobe by launching a promotion ... all over the discount of 80% off, like a cheap ... ship. The company’s chic wedding dresses are among the hottest ...
(Date:12/24/2014)... 2014 The report offers details on ... various market dynamics such as the key trends, the ... wait time for U.S. sports medicine, the impact of ... the challenges faced by the market. , Browse report ... The report also provides an overview of the global ...
(Date:12/24/2014)... 24, 2014 Dental implants benefit millions ... tooth replacement. They offer the strongest and most secure ... other forms of tooth replacement. They will never slip ... adjacent teeth for support, and they prevent the jaw ... told that they are not suitable candidates for dental ...
(Date:12/24/2014)... Final Cut Pro X plugin ... Film Studios. , “The ProDenoise plugin that allows users to ... said Christina Austin, CEO of Pixel Film Studios. “ProDenoise is ... X editors toolbox.” , Final Cut Pro X users can ... footage with ProDenoise from Pixel Film Studios. ProDenoise can quickly ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... vaccine that U.S. officials are preparing to test in West ... vaccine produced a safe and potent immune response in Africans. ... more than 100 Ugandans in 2009 and 2010, prompted the ... protect a person against infection by Ebola, said study author ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4
... new study shows exercise may allow for better brain ... mentally engaged.// ,Researchers from the Oregon Health and ... causes physical changes in the brain. Researchers say they ... want environmental factors such as smoking, drinking, and obesity ...
... new study shows a novel new drug is beneficial ... cells and is the first in a new class ... ,The drug is called cytotoxic T-lymphocyte-associated antigen 4-IgG1 or ... the treatment of rheumatoid arthritis. Researchers from Belgium conducted ...
... shows bone marrow stem cells may help restore damaged ... the American Heart //Association’s Scientific Sessions 2003 presented their ... that took place in 2001. Results from that trial ... his own bone marrow had improved heart function. ...
... say women will now have to talk seriously with their ... ,Pancreatic cancer affects only 31,000 Americans a year, but it ... study of 88,000 nurses found that those who took two ... had a 58 percent higher risk of pancreatic cancer.,Researchers expected ...
... A new study shows the symptoms women experience before ... the symptoms they expect to experience. ,Researchers interviewed ... and were discharged from five different medical sites. The ... asked the women to identify their symptoms before their ...
... new study shows children who are obese are more ... not overweight. ,Researchers from the University of Michigan studied ... The children and their parents took part in the ... weight, behavior, physical and mental health, education, demographic, and ...
Cached Medicine News:Health News:Aspirin usage linked with pancreatic cancer 2
... to match the pace and unique needs ... on Philips strong heritage in patient monitoring, ... has highly flexible screen configuration; an extensive ... such as Event Surveillance, EASI derived 12-lead ...
... is a comprehensive vital sign monitor. , ,Adult, ... products for efficiency in patient care., ,Standard Functions: ... - Temp - Multi-gas Sensor (HAL, ENF, ISO, ... ,Optional Functions: ,5-Lead ECG - FiO 2 - ...
... CS makes the outstanding ... CS even more flexible. ... Technologies, the Wireless Propaq ... ethernet Local Area Networks ...
... The Acuity Central Monitoring Station ... for up to 60 patients from ... interface uses simple point and click ... trackball. The clinician can initiate or ...
Medicine Products: